During pregnancy, maternal folate receptor alpha (FRa) autoantibodies could block folate transfer to the fetus and increase the risk of neural tube defects.
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A low titer of this antibody in a fraction of the adult population appears to be non-pathologic. Postnatally acquired FR autoantibodies blocking folate transport to the brain have been associated with the infantile-onset cerebral folate deficiency syndrome, 4 which in a number of patients manifests as low-functioning autism with neurological deficits. 5 In a US population with autism spectrum disorder (ASD), either the blocking-or the binding-type autoantibody was detected in 75% of the children and high-dose folinic-acid supplementation improved the core symptoms of autism in these children. 6 We studied a population of infantile autism, non-autistic controls with developmental deficits and their parents in Belgium (research project supported by FNRS Belgium No: 3.4.540.09.F). Serum was tested for FRa-blocking autoantibodies as described previously. 4 Plasma homocysteine and serum folate were also measured. The samples were coded and blinded to all analysis. Table 1 summarizes the results for 75 children with infantile autism and their parents compared with 30 non-autistic controls with developmental delay. A total of 74 mothers of children with autism and 50 fathers were available for testing. Although there was an expected preponderance of males in the autistic group, age and serum folate for both groups were similar, while homocysteine was in the normal range (5 --15 mmol l À1 ). Blocking FR antibodies in autism showed a significantly higher prevalence of 47% compared with only 3.3% in developmentally delayed non-autistic children (Po0.001). In 27 of the 35 autistic children, both parents tested negative, suggesting postnatal development of FR autoimmunity as the likely mechanism. In 8 of the 35 children with positive FR antibodies, either the mother or the father also tested positive, suggesting an additional role of parental antibodies in the pathogenesis. Moreover, in the 40 autistic children testing negative, FR antibodies were present in 10 mothers and 4 fathers, while in three families both parents tested positive. These findings suggest that FR autoimmunity in either one or both parents may contribute to the development of autism in their offspring. Compared with the presence of FR antibodies in only one child with attention deficit hyperactivity disorder and both his parents among the 30 non-autistic controls, the overall results for the autistic population showed a higher prevalence of FR antibodies in 19 mothers and 9 fathers.
Repeated testing of seven autistic children showed wide fluctuations of FRa antibody and two children tested over 6 weeks showed weekly variations ranging from 0 to 1.14 pmol FRablocked per ml serum. Fluctuations in antibody titer seen in most autoimmune disorders may be driven by a multitude of factors, among them, immune stimulation by antigen expression or exposure and antigen --antibody clearance. Free antibody in serum likely represents excess after saturating membrane-bound FRa antigen. Therefore, multiple testing at separate intervals should be done to rule out FR autoimmunity. The short-term effects of rising FR-antibody titers have been correlated with increased aggression and loss of communicative skills. 5 Even in children testing negative, the presence of maternal antibodies may have a role in prenatal brain development and autism. In families where only the father tested positive, the 6 provide evidence in support of testing for FR autoantibodies in ASD. Previous study 7 has implicated milk consumption as a trigger in stimulating antibody production. What is remarkable is that most of the children with ASD have been on a milk-free diet for years because of multiple gastrointestinal problems and yet are positive for the FR autoantibody. Acute tryptophan depletion (ATD) is a widely used dietary method to assess the function of serotonin (5-HT) in cognition and behavior. As such, ATD-based studies have implicated 5-HT in numerous cognitive functions and has advanced our understanding of depression and affective disorders. However, recently two critical reports have been published that call the validity of ATD into question. 1, 2 In a feature review, van Donkelaar et al. 2 recently pointed out that ''caution is required when interpreting ATD in terms of a selective serotonergic effect''. These authors argue that there is insufficient proof for altered 5-HT release following ATD and point to alternative mechanisms through which ATD can exert its effects (see also Feenstra et al. 1 ).
CONFLICT OF INTEREST
In
, advanced online) now comment that the evidence that ATD alters central 5-HT function is at least persuasive. In particular, they disagree with the view that there is insufficient proof that ATD alters 5-HT release (and consequently, neurotransmission). As the assumed ATD-induced reduction of 5-HT release is central to the validity of ATD as a method to assess 5-HT function, the possible effects that selective serotonin reuptake blockers (SSRIs) have on 5-HT synthesis need a closer examination.
Previously we reviewed the literature and concluded that there is no evidence for ATD-induced decreases in rodent, primate or human 5-HT release, unless 5-HT synthesis is already decreased or 5-HT utilization is increased. 1 In this review, it is pointed out that the SSRIs that are often used to allow quantification of in vivo 5-HT release have been shown to decrease 5-HT synthesis. Crockett et al.
3 now object that these drugs do not reach the brain concentrations needed to affect 5-HT release through 5-HT 1A receptors. However, several reports present data showing that, irrespective of the mechanism, SSRIs such as citalopram do, in fact, decrease the 5-HT synthesis 4--6 when given in doses that lead to brain concentrations in the range of 0.1--0.3 mM.
7--9 These concentrations are expected in brain tissue after microdialysis perfusion of for example, 1 mM citalopram, as has been used in many studies (see Feenstra et al. 1 ). This suggests that 5-HT synthesis will be affected by these conditions and that the threshold for ATD to affect 5-HT release will be lowered. As such, the microdialysis studies embraced by Crockett et al. 3 to show ATD-induced reductions in 5-HT release do not provide the direct evidence that is needed to show that ATD decreases extracellular 5-HT concentrations.
Crockett et al. 3 support the view that more conclusive evidence might be obtained by applying ATD under conditions of increased 5-HT activity, such as motor activity or stress. 1 However, the present debate calls for an experimental evidence based on physiological, emotional or cognitive challenges such as applied in the human studies, rather than physical stressors such as footshocks. Moreover, using stress as a challenge may lead to complex changes in the 5-HT system, as 5-HT synthesis may be stimulated by some stressors. 10 That would possibly make stress not the ideal test for changes in 5-HT release after ATD.
In light of the impact ATD studies have on current theories of serotonergic function, it is imperative that the evidence that ATD affects 5-HT release and transmission is carefully weighed. Moreover, the manner in which ATD affects (peripheral) serotonergic function and known inter-subject vulnerability to 5-HT modulation needs to be taken into account. 1, 2 It is important that these issues are now brought under the attention of the scientific community and that 5-HT release and transmission is studied following ATD during the execution of cognitive/affective tasks. Only by providing experimental evidence in favor of altered 5-HT function can the claims made by Crockett et al. 3 concerning ATD be upheld and its validity shown. Until then the objections brought forth by van Donkelaar et al. 2 need to be taken into consideration.
